Observations on the systemic effect of topical clobetasol propionate (Dermovate)

J A CARRUTHERS, P J AUGUST, R C D STAUGHTON

British Medical Journal, 1975, 4, 203-204

Summary

Topical application of clobetasol propionate in a strength of 0.05% in cream or ointment (Dermovate) suppressed the hypothalamic-pituitary-adrenal axis in both normal people and patients with diseased skin. In normal people the 9 am serum cortisol level was suppressed when between 45 and 90 g was applied weekly. Insulin stress test results in patients with diseased skin showed an abnormally small response after long-term application of similar amounts. We conclude that long-term administration should be restricted to less than 50 g a week.

Introduction

Clobetasol propionate, a new fluorinated topical corticosteroid, is widely used in both hospital and general practice in a strength of 0.05% in a cream or ointment base (Dermovate). It appears to be the most potent topical corticosteroid available.¹ Adverse reactions to its use have included iatrogenic Cushing's syndrome,² hypothalamic-pituitary-adrenal (HPA) axis suppression,^{3 4 5} and the precipitation of generalised pustular psoriasis,⁶ which are well known complications of treatment with systemic corticosteroids.⁷ These problems prompted an attempt to quantify the effects of the preparation on the HPA axis in both normal people and patients with skin disease.

Materials and methods

Normal people—male volunteers aged 22 to 30 years applied clobetasol propionate cream daily either to the whole body, excluding head, axillae, and genitalia (approximately 90% of the body surface area), or to the limbs alone (approximately 50% of the body surface area). Either 45 g or 90 g or 175 g was used weekly (a quarter, half, or whole 25-g tube daily). Blood was taken between 9 and 9.30 am each day for estimation of serum cortisol by a competitive binding technique⁸ that gives true readings for cortisol even in the presence of clobetasol propionate.

Patients—Insulin stress tests were performed on 13 patients with eczema or psoriasis affecting 5-50% of the body surface area who had been using the cream or ointment preparation for 10 weeks to 18 months. In the test⁹ an intravenous injection of insulin (0.1 IU/kg body weight) provokes a hypoglycaemia of less than 1.67 mmol/l (30 mg/100 ml). This is an adequate stimulus for a maximal rise in serum cortisol to occur. The test measures the corporate integrity of the HPA axis.

Results

NORMAL PEOPLE

Two of the volunteers applied 45 g clobetasol propionate weekly to the whole body, and a further two applied this amount to the limbs only. In all cases the serum cortisol levels remained normal (fig 1).

Three volunteers applied 90 g clobetasol propionate cream weekly to their limbs (fig 1). In two the serum cortisol was completely suppressed by the eighth day; they then extended application of this amount to the whole body for a further week and suppression persisted. The third volunteer failed to show suppression and had a normal serum cortisol level throughout. In his case the experiment was repeated with identical results. Two further volunteers applied the cream to the whole body from the outset and also showed profound adrenal suppression. Fig 2 shows serial cortisol levels for one of these. The levels of the other rose, despite continued application, when he underwent an episode of stress associated with the delivery of his wife's first child.

FIG 1—Lowest 9 am serum cortisol levels during application of clobetasol propionate cream in normal people.

Conversion: SI to traditional units—Cortisol: 1 nmol/l $\approx$ 0.036 μ g/100 ml.

FIG 2—Response of one normal person to application of 90 g clobetasol propionate cream weekly to whole body.

Three volunteers applied 175 g of cream to the whole body (fig 1), which rapidly suppressed the serum cortisol levels in all three. One became feverish on the fifth day of application, and his serum cortisol returned to normal. In the other two the cortisol level returned to normal within one to four days of stopping application.

Department of Dermatology, St Thomas's Hospital, London SE1 7EH
J A CARRUTHERS, MA, MRCP, registrar
P J AUGUST, MB, MRCP, senior registrar
R C D STAUGHTON, MA, MRCP, registrar

PATIENTS

Figs 3 and 4 show a gradual reduction in the resting and stress cortisol levels respectively in the patients with increasing amounts of clobetasol applied. The lower limits of normal for these values were crossed when 50-100 g was applied weekly. One patient using only 40 g weekly had a reduced peak response in the insulin stress test. He had eczema of the hands and feet with severe cutaneous atrophy and may thus have absorbed greater amounts of the preparation.

FIG 3—Resting 9 am serum cortisol levels after long-term use of clobetasol propionate.

FIG 4—Peak cortisol levels during insulin stress after long-term use of clobetasol propionate.

Discussion

Our data agree with previous reports²⁻⁵ that topically applied clobetasol propionate in a strength of 0.05% (Dermovate)

may cause profound suppression of the HPA axis. Normal people applying 45 g clobetasol propionate cream weekly did not show significant suppression, whereas all but one of those applying 90 g weekly showed profound suppression. This suggests that in most normal people the "safe" threshold for the amount applied weekly lies between 45 and 90 g. We are unable to explain why one of the normal people failed to suppress at all with 90 g weekly and feel that this represents individual variation in the handling of the drug. Because of this we suspect that a few patients may be able to apply large amounts of the drug without developing features of Cushing's syndrome. But, as our data on patients show, in most cases there appeared to be a linear relationship between the amount of the preparation applied and HPA axis suppression. Patients applying over 50 g weekly all had either a reduced 9 am serum cortisol level or a reduced peak insulin stress test level. Those using over 100 g weekly showed profound suppression and developed features of Cushing's syndrome. On withdrawal they suffered symptoms of adrenocortical insufficiency and developed pustular psoriasis.

Patients find preparations of clobetasol propionate gratifyingly effective for treating their stubborn dermatoses, especially psoriasis. They also appreciate the euphoriant effect, hence overenthusiastic application is particularly apt to occur. We conclude that patients should be warned against using more than 50 g a week. Their physicians should exercise as much caution with this cream as with systemic corticosteroids.

We thank Drs M M Black, H J Wallace, and G C Wells for permission to study their patients and for encouragement and helpful advice. The cortisol estimations and insulin stress tests were performed in Professor R V Brooks's department, and we are grateful for his and Dr Clara Lowy's help.

Requests for reprints should be addressed to: Dr J A Carruthers, St John's Hospital for Diseases of the Skin, Lisle Street, London WC2H 7BJ.

References

- 1 Sparkes, C G, and Wilson, L, *British Journal of Dermatology*, 1974, **90**, 197.
- 2 Staughton, R C D, and August, P J, *British Medical Journal*, 1975, **2**, 419.
- 3 Tan, R S-H, *Proceedings of the Royal Society of Medicine*, 1974, **67**, 719.
- 4 Feiwel, M, and Kelly, W F, *Lancet*, 1974, **2**, 112.
- 5 Ortega, E, Burdick, K H, and Segre, E J, *Lancet*, 1975, **1**, 1200.
- 6 Boxley, J D, Dawber, R P R, and Summerly, R, *British Medical Journal*, 1975, **2**, 255.
- 7 Baker, H, and Ryan, T J, *British Journal of Dermatology*, 1968, **80**, 771.
- 8 Murphy, B E P, *Journal of Clinical Endocrinology and Metabolism*, 1967, **27**, 973.
- 9 Landon, J, Wynn, V, and James, V H T, *Journal of Endocrinology*, 1963, **27**, 183.

SHORT REPORTS

Infusion apparatus for parenteral nutrients

The use of parenteral nutrition is achieving wide acceptance in many acute medical and surgical situations. To provide total parenteral nutrition for seriously ill patients the infusion of several nutrient solutions simultaneously may be required to provide daily metabolic requirements. Numerous studies have confirmed that the concomitant use of amino-acids with carbohydrate or fat emulsion provides a utilizable anabolic protein source for parenteral nutrition regimens.¹ Increased efficiency of a parenteral diet is achieved when the calories are provided by both carbohydrate and fat,² and optimal metabolic usage requires that carbohydrates, potassium, and amino-acid sources be administered simultaneously.^{3,4} Many ill patients lose abnormal amounts of body fluids, and often require additional water and electrolyte supplements, together with vitamins and minerals. In patients with high metabolic demands, insulin and glucose regimens provide a valuable additional approach to the problem.⁵ The problems

of chemical incompatibility between these various solutions and the risks of infection when such solutions are mixed have restricted the choice of suitable regimens available to clinicians. We describe an apparatus designed to overcome the problems of multiple intravenous fluid infusions.

Design of Apparatus

The system we have developed (see fig) allows great flexibility in prescribing intravenous solutions for seriously ill patients, whose metabolic requirements may be constantly changing. Though any combination of solutions can be used with this apparatus within the limitations of chemical compatibility, we describe a typical regimen for complete intravenous nutrition which has proved satisfactory in practice.

Bottles 1 and 2 contain amino-acid solutions and a calorie source respectively. The following solutions have been used concurrently and found to be compatible: amino-acid solutions—Aminoplex-14, Vamin, Trophosan, and Aminosol; calorie solutions—sorbitol, hypertonic glucose, fructose, and Intralipid. Bottle 3 contains normal saline or dextrose 5%, with additional potassium supplements and multivitamin solutions as required. Bottle 4